<?xml version="1.0" encoding="UTF-8"?>
<p>Motavizumab is a recombinant humanized mAb that binds to a 24-residue, linear, conformational epitope FFL on the RSV F glycoprotein (
 <xref rid="ref170" ref-type="bibr">Zhu et al., 2011</xref>). Preclinical studies in cotton rats demonstrated that the mAb decreased RSV titers more than 50 times in lungs in comparison to palivizumab (
 <xref rid="ref163" ref-type="bibr">Wu et al., 2007</xref>). Phase 1 and 2 clinical trials showed that motavizumab is well tolerated in healthy adults and premature infants as well as in high-risk children with chronic lung disease of prematurity (
 <xref rid="ref1" ref-type="bibr">Abarca et al., 2009</xref>; 
 <xref rid="ref107" ref-type="bibr">O’Brien et al., 2015</xref>). The results of a recent phase 3 clinical trial to prevent serious RSV disease in healthy term infants indicated that motavizumab reduced the proportion of infants admitted to the hospital with RSV (
 <xref rid="ref107" ref-type="bibr">O’Brien et al., 2015</xref>).
</p>
